stockrow
Friday 6 November 2026
Export TEVA’s income statement to Excel — free account
Teva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
42.44
0.66
+1.58%
Follow TEVA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
25.17 | 21.99 | 53.78 | 87.86 |
P/S ratio |
2.07 | 2.01 | 2.28 | 2.68 | |
P/FCF ratio |
30.23 | 28.28 | 28.17 | 34.77 | |
P/Operating CF |
30.86 | (870.47) | 96.03 | 191.59 | |
P/B ratio |
4.52 | 4.23 | 5.09 | 5.78 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.84 | 2.75 | 3.03 | 3.41 | |
EV/EBITDA |
15.50 | 14.52 | 20.91 | 25.18 | |
EV/Operating CF |
29.71 | 27.83 | 27.61 | 33.22 | |
EV/FCF |
41.44 | 38.75 | 37.41 | 44.28 | |
Quick Ratio |
0.54 | 0.53 | 0.46 | 0.51 | |
Current Ratio |
1.04 | 1.01 | 0.88 | 0.95 | |
Net Debt/EBITDA |
40.40 | 14.46 | 82.40 | 13.17 | |
Debt/Assets |
41.24% | 41.53% | 41.63% | 41.75% | |
Debt/Equity |
2.12 | 2.02 | 2.14 | 2.09 | |
Asset Turnover |
0.43 | 0.44 | 0.43 | 0.43 | |
Operating CF/Net income |
2.41 | (0.11) | (0.71) | 1.03 | |
Capex/Depreciation |
(0.55) | (0.53) | (0.42) | (0.30) | |
Research and Development Expense of Revenue |
5.65% | 5.58% | 23.42% | 6.76% | |
Selling, General and Administrative Expense of Revenue |
23.82% | 25.11% | 24.96% | 22.91% | |
Intangible Assets out of Total Assets |
0.49 | 0.49 | 0.48 | 0.48 | |
Share Based Compensation of Revenue |
1.08% | 1.08% | 0.97% | 0.86% | |
Graham Net Nets |
(0.53) | (0.52) | (0.46) | (0.38) | |
Graham Number |
13.89 | 14.82 | 9.72 | 8.33 | |
Earnings Yield |
3.97% | 4.55% | 1.86% | 1.14% | |
Free Cash Flow Yield |
3.31% | 3.54% | 3.55% | 2.88% | |
Revenue per Share |
4.11 | 3.44 | 3.56 | 3.77 | |
Operating CF per Share |
1.01 | (0.03) | 0.35 | 0.21 | |
Capex per Share |
(0.12) | (0.11) | (0.09) | (0.06) | |
Free Cash Flow per Share |
0.89 | (0.14) | 0.27 | 0.14 | |
Cash per Share |
3.11 | 3.24 | 3.14 | 3.50 | |
Shareholders Equity per Share |
6.91 | 7.12 | 6.66 | 6.85 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.91 | 7.12 | 6.66 | 6.85 | |
Free Cash Flow |
1,016.00 | (166.00) | 310.00 | 168.00 | |
Working Capital |
490.00 | 178.00 | (1,886.00) | (823.00) | |
Capital Expenditures |
(142.00) | (126.00) | (101.00) | (73.00) | |
Net Current Asset Value |
(18,888.00) | (18,099.00) | (18,340.00) | (17,455.00) | |
EV/EBIT |
22.70 | 20.84 | 34.52 | 43.56 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
16.56 | 15.21 | 26.00 | 34.20 | |
| Other line items | |||||
Average Receivables |
3,384.00 | 3,388.50 | 3,528.50 | 3,823.50 | |
Average Payables |
2,367.00 | 2,443.00 | 2,609.50 | 2,453.00 | |
Average Inventory |
3,093.00 | 3,211.50 | 3,359.00 | 3,248.00 | |
Average Assets |
40,037.00 | 39,227.50 | 39,994.00 | 39,949.00 | |
Average Common Equity |
6,647.00 | 7,250.50 | 7,295.00 | 7,619.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026